SG 1408
Alternative Names: SG-1408Latest Information Update: 19 Jan 2023
At a glance
- Originator Hangzhou Sumgen Biotech
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 19 Jan 2023 Phase-I clinical trials in Cancer in China (Parenteral) prior to December 2022 (Hangzhou Sumgen Biotech, December 2022)
- 10 Jun 2022 Sumgen Biotech plans to initiate phase I trial in Cancer in 2022 (Sumgen Biotech pipeline, June 2022)
- 10 Jun 2022 Preclinical trials in Cancer in China (Parenteral) before June 2022 (Sumgen Biotech pipeline, June 2022)